ArticleBMC immunology2017
Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.
Article in BMC immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 21 citations in OpenAlex.
- Effect ofBioMed research international · 2021Trial
- Article
- Bioinformatic development of a recombinant trivalent synthetic protein construct using PTXa, Tox, and TetX toxins as a DTP vaccine candidate.Archives of Razi Institute · 2024Article
- Adverse Events Following Immunizations in Infants Under 1 Year of Age in Lorestan Province, Western Iran.Journal of preventive medicine and public health = Yebang Uihakhoe chi · 2023Article
- Factors associated with pentavalent vaccine coverage among 12-23-month-old children in Afghanistan: A cross-sectional study.PloS one · 2023Article
- Adverse events following pediatric immunization in an Indian city.Clinical and experimental vaccine research · 2021Article
- Immunogenicity and Complications of the Pentavalent Vaccine in Iranian Children.Frontiers in pediatrics · 2021Article
- Estimation of the wastage rate of MMR and pentavalent vaccines in open and closed vials in three western provinces of Iran.Heliyon · 2020Article
- The Comparison of the Adverse Events of Pentavalent Vaccine and DPT Vaccine in 2-6 Months Infants in Iran: A National Study.Annals of global health · 2020Article
- Correction to: Adverse events following immunization with pentavalent vaccine: experiences of newly introduced vaccine in Iran.BMC immunology · 2017Article
- Comparative Assessment of the Incidence of Fever among Prophylactic Acetaminophen-Treated and Non-Treated Infants after Pentavalent Vaccine in a Tertiary Institution in Abakaliki, Southeast Nigeria.Nigerian medical journal : journal of the Nigeria Medical AssociationArticle
Corrections and comments
- Erratum issued
Authors and funding
9 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe most important factors that affect the incidence of vaccine-related complications are the constituent biological components of the vaccine, injection site reactions, age and sex. The aim of this study is to determine the incidence rate of adverse events following immunization with pentavalent vaccine (DTPw-Hep B-Hib (PRP-T) vaccine (pentavac) (adsorbed) is manufactured by Serum Institute of India ltd), which was introduced in Iran in November 2014. It is important to monitor vaccine-related adverse events because of the role of vaccine safety in immunization program success.
methodsThis study was a mixed cohort study that included 1119 children less than 1 year of age. In 2015, the children were referred to Hamadan health centers to receive pentavalent vaccine at 2, 4 and 6 months of age. The data were collected from the parents of the children using a questionnaire that was administered either face-to-face or by telephone. The cumulative incidence of side effects and risk ratio was reported with 95% confidence intervals (CI). Chi-squared tests and logistic regressions were used to investigate the association between the variables.
resultsThe cumulative incidence rate of pentavalent-related adverse events during 48 h following immunization was estimated to be 15.8% for swelling, 10.9% for redness, 44.2% for pain, 12.6% for mild fever, 0.1% for high fever, 20.0% for drowsiness, 15.0% for loss of appetite, 32.9% for irritability, 4.6% for vomiting and 5.5% for persistent crying. There is no evidence for the occurrence of convulsion and encephalopathy among children who receive pentavalent vaccines.
conclusionFurther large studies with long time follow up are required to address rare events include convulsions, encephalopathy or persistent crying. However, Findings urge immunization programs to use pentavalent vaccinations and to continue implementing the current immunization program in children under 1 year of age.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.